www.specialtypharmacycontinuum.com
Open in
urlscan Pro
45.60.66.7
Public Scan
URL:
https://www.specialtypharmacycontinuum.com/Online-First/Article/07-24/17-7-Million-More-AIDS-Related-Deaths/74408
Submission: On December 31 via api from US — Scanned from AU
Submission: On December 31 via api from US — Scanned from AU
Form analysis 2 forms found in the DOM
<form class="gsc-search-box gsc-search-box-tools" accept-charset="utf-8">
<table cellspacing="0" cellpadding="0" role="presentation" class="gsc-search-box">
<tbody>
<tr>
<td class="gsc-input">
<div class="gsc-input-box" id="gsc-iw-id1">
<table cellspacing="0" cellpadding="0" role="presentation" id="gs_id50" class="gstl_50 gsc-input" style="width: 100%; padding: 0px;">
<tbody>
<tr>
<td id="gs_tti50" class="gsib_a"><input autocomplete="off" type="text" size="10" class="gsc-input" name="search" title="search" aria-label="search" id="gsc-i-id1" dir="ltr" spellcheck="false"
style="width: 100%; padding: 0px; border: none; margin: 0px; height: auto; outline: none;"></td>
<td class="gsib_b">
<div class="gsst_b" id="gs_st50" dir="ltr"><a class="gsst_a" href="javascript:void(0)" title="Clear search box" role="button" style="display: none;"><span class="gscb_a" id="gs_cb50" aria-hidden="true">×</span></a></div>
</td>
</tr>
</tbody>
</table>
</div>
</td>
<td class="gsc-search-button"><button class="gsc-search-button gsc-search-button-v2"><svg width="13" height="13" viewBox="0 0 13 13">
<title>search</title>
<path
d="m4.8495 7.8226c0.82666 0 1.5262-0.29146 2.0985-0.87438 0.57232-0.58292 0.86378-1.2877 0.87438-2.1144 0.010599-0.82666-0.28086-1.5262-0.87438-2.0985-0.59352-0.57232-1.293-0.86378-2.0985-0.87438-0.8055-0.010599-1.5103 0.28086-2.1144 0.87438-0.60414 0.59352-0.8956 1.293-0.87438 2.0985 0.021197 0.8055 0.31266 1.5103 0.87438 2.1144 0.56172 0.60414 1.2665 0.8956 2.1144 0.87438zm4.4695 0.2115 3.681 3.6819-1.259 1.284-3.6817-3.7 0.0019784-0.69479-0.090043-0.098846c-0.87973 0.76087-1.92 1.1413-3.1207 1.1413-1.3553 0-2.5025-0.46363-3.4417-1.3909s-1.4088-2.0686-1.4088-3.4239c0-1.3553 0.4696-2.4966 1.4088-3.4239 0.9392-0.92727 2.0864-1.3969 3.4417-1.4088 1.3553-0.011889 2.4906 0.45771 3.406 1.4088 0.9154 0.95107 1.379 2.0924 1.3909 3.4239 0 1.2126-0.38043 2.2588-1.1413 3.1385l0.098834 0.090049z">
</path>
</svg></button></td>
<td class="gsc-clear-button">
<div class="gsc-clear-button" title="clear results"> </div>
</td>
</tr>
</tbody>
</table>
</form><form class="gsc-search-box gsc-search-box-tools" accept-charset="utf-8">
<table cellspacing="0" cellpadding="0" role="presentation" class="gsc-search-box">
<tbody>
<tr>
<td class="gsc-input">
<div class="gsc-input-box" id="gsc-iw-id2">
<table cellspacing="0" cellpadding="0" role="presentation" id="gs_id51" class="gstl_51 gsc-input" style="width: 100%; padding: 0px;">
<tbody>
<tr>
<td id="gs_tti51" class="gsib_a"><input autocomplete="off" type="text" size="10" class="gsc-input" name="search" title="search" aria-label="search" id="gsc-i-id2" dir="ltr" spellcheck="false"
style="width: 100%; padding: 0px; border: none; margin: 0px; height: auto; outline: none;"></td>
<td class="gsib_b">
<div class="gsst_b" id="gs_st51" dir="ltr"><a class="gsst_a" href="javascript:void(0)" title="Clear search box" role="button" style="display: none;"><span class="gscb_a" id="gs_cb51" aria-hidden="true">×</span></a></div>
</td>
</tr>
</tbody>
</table>
</div>
</td>
<td class="gsc-search-button"><button class="gsc-search-button gsc-search-button-v2"><svg width="13" height="13" viewBox="0 0 13 13">
<title>search</title>
<path
d="m4.8495 7.8226c0.82666 0 1.5262-0.29146 2.0985-0.87438 0.57232-0.58292 0.86378-1.2877 0.87438-2.1144 0.010599-0.82666-0.28086-1.5262-0.87438-2.0985-0.59352-0.57232-1.293-0.86378-2.0985-0.87438-0.8055-0.010599-1.5103 0.28086-2.1144 0.87438-0.60414 0.59352-0.8956 1.293-0.87438 2.0985 0.021197 0.8055 0.31266 1.5103 0.87438 2.1144 0.56172 0.60414 1.2665 0.8956 2.1144 0.87438zm4.4695 0.2115 3.681 3.6819-1.259 1.284-3.6817-3.7 0.0019784-0.69479-0.090043-0.098846c-0.87973 0.76087-1.92 1.1413-3.1207 1.1413-1.3553 0-2.5025-0.46363-3.4417-1.3909s-1.4088-2.0686-1.4088-3.4239c0-1.3553 0.4696-2.4966 1.4088-3.4239 0.9392-0.92727 2.0864-1.3969 3.4417-1.4088 1.3553-0.011889 2.4906 0.45771 3.406 1.4088 0.9154 0.95107 1.379 2.0924 1.3909 3.4239 0 1.2126-0.38043 2.2588-1.1413 3.1385l0.098834 0.090049z">
</path>
</svg></button></td>
<td class="gsc-clear-button">
<div class="gsc-clear-button" title="clear results"> </div>
</td>
</tr>
</tbody>
</table>
</form>Text Content
× ADVERTISEMENT Register Login × search * SECTIONS * Ask The Expert * Classifieds * Clinical * Covid-19 * FDA News * Industry News * Online First * Operations & Management * Opinion * Pharmacy Technology Report * Policy * Review Articles * DIGITAL ISSUE * CONFERENCES * Conference Calendar * Conference News * EDUCATION * CME * Monographs & Whitepapers * VIDEOS * SUPPLEMENTS * Buyer's Guide * Corporate Profiles * Pharmacy Technology Report * SUBSCRIBE * e-Newsletter * Print Subscription * Renew Print Subscription * Social Media * CONTACT * Advertise * About * Contact Us Search × search NIOSH RELEASES UPDATED ‘LIST OF HAZARDOUS DRUGS IN HEALTHCARE SETTINGS’ DECEMBER 20, 2024 FDA APPROVES RYONCIL FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS DECEMBER 19, 2024 ENVISIONING THE FUTURE OF RFID IN HOSPITAL PHARMACY DECEMBER 19, 2024 ONLINE FIRST JULY 26, 2024 FAILING TO MEET GLOBAL TARGETS MEANS 17.7 MILLION MORE AIDS-RELATED DEATHS Originally published by our sister publication Infectious Disease Special Edition By Marie Rosenthal, MS Failing to meet UNAIDS’s “95-95-95” HIV targets would entail tremendous human and economic consequences throughout the world, according to an analysis that will be presented at AIDS 2024, held in Munich (poster 11028). The study, presented by Erik Lamontagne, PhD, a senior economist at UNAIDS, estimated the human and economic cost of failing to meet the “95-95-95” To read the full story, Register or Login Register / Login MORE IN ONLINE FIRST ZEPBOUND APPROVED FOR OBSTRUCTIVE SLEEP APNEA The FDA approved tirzepatide (Zepbound, Eli Lilly) as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. The injectable medication should be used with a reduced-calorie diet and increased physical activity, the company noted in a press release. DECEMBER 20, 2024 FDA DECLARES END TO TIRZEPATIDE SHORTAGE The FDA has officially removed tirzepatide from its drug shortage list, meaning that compounding pharmacies will no longer be allowed to make their own versions of the drug. But compounding advocates say the agency's decision may actually harm continued access to the weight-loss medication. DECEMBER 20, 2024 NIOSH RELEASES UPDATED ‘LIST OF HAZARDOUS DRUGS IN HEALTHCARE SETTINGS’ The National Institute for Occupational Safety and Health (NIOSH), a division of the CDC, released an updated version of its List of Hazardous Drugs in Healthcare Settings, 2024. But safe handling experts warned that the updated list still is nearly a decade out of date when it comes to FDA-approved cytotoxic agents. DECEMBER 20, 2024 DIGITAL ISSUE December 2024 -------------------------------------------------------------------------------- MOST POPULAR * THE SPECIALTY PHARMACIST’S ROLE IN RHEUMATOID ARTHRITIS Review Articles DECEMBER 16, 2024 * GLP-1 ‘SHADOW SYSTEM’ OF INTERNET SELLERS POSES A MAJOR SAFETY CONCERN Policy DECEMBER 13, 2024 * 'A WAR BREWING’ BETWEEN GLP-1 MANUFACTURERS AND COMPOUNDERS Online First NOVEMBER 1, 2024 * STEROIDS STILL THE MAINSTAY TREATMENT FOR CGVHD Clinical DECEMBER 15, 2024 -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- PHARMACY TECHNOLOGY REPORT ENVISIONING THE FUTURE OF RFID IN HOSPITAL PHARMACY RFID technology is already transforming inventory management, overcoming limitations of barcodes such as duplicate ... HOSPITAL PHARMACIES COMBINE TECH SOLUTIONS FOR WORKFORCE CHALLENGES Hospital pharmacies facing significant growth, along with pressure from workforce shortages, are deploying ... -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ONLINE FIRST ZEPBOUND APPROVED FOR OBSTRUCTIVE SLEEP APNEA The FDA approved tirzepatide (Zepbound, Eli Lilly) as the first prescription medicine for adults with ... FDA DECLARES END TO TIRZEPATIDE SHORTAGE The FDA has officially removed tirzepatide from its drug shortage list, meaning that compounding pharmacies will no ... -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ONLINE FIRST ZEPBOUND APPROVED FOR OBSTRUCTIVE SLEEP APNEA The FDA approved tirzepatide (Zepbound, Eli Lilly) as the first prescription medicine for adults with ... FDA DECLARES END TO TIRZEPATIDE SHORTAGE The FDA has officially removed tirzepatide from its drug shortage list, meaning that compounding pharmacies will no ... -------------------------------------------------------------------------------- Archives November 2024 October 2024 September 2024 August 2024 MORE -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- Specialty Pharmacy Continuum (SPC) strives to provide accurate, relevant, and up-to-date clinical and business information to specialty pharmacists, home infusion practitioners, managed care organizations and other key providers of specialty pharmacy. HOME ABOUT SUBSCRIPTION CONTACT ARCHIVES PRIVACY POLICY ENEWSLETTER Click here to sign up to receive our eNewsletter. MY ACCOUNT LOGIN REGISTER SOCIAL MEDIA @specialtypharm SpecialtyPharmacyContinuum Specialty Pharmacy Continuum MCMAHON WEBSITES * Anesthesiology News Clinical Oncology News Gastroenterology & Endoscopy News General Surgery News Infectious Disease Special Edition Pain Medicine News Pharmacy Practice News Specialty Pharmacy Continuum CMEZone.com McMahon Custom Media McMahon Group Pharmacy Technology Report OR Management News Copyright © 2004-2024 McMahon Publishing unless otherwise noted. Specialty Pharmacy Continuum and SpecialtyPharmacyContinuum.com are part of McMahon Publishing. All rights reserved. Reproduction in whole or in part without permission is prohibited. Thank you for your interest in our website! Our Privacy Policy has been updated. In order to continue on to our site, you should read the policy statement, which includes our cookie policy, and click Yes I Accept. For those who do not click Yes, access to our site will be denied. Yes I Accept Do not Accept × Close CHECK OUT OUR NEW CLINICAL TAB! We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore! Close Check it out